Back to search results

Topical Ketotifen 0.25% for Secondary Vestibulodynia

Abroad (travel likely)RecruitingPHASE2

Conditions

Provoked Vestibulodynia · Secondary Provoked Vestibulodynia · Vulvodynia · Vulvary Pain Disorders · Neuroproliferative Vestibulodynia · Mast Cell-mediated Neuroinflammation · Instertional Dyspareunia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The Center for Vulvovaginal Disorders - Washington, DC, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Chailee Moss, MD) · chaileemossmd@vulvodynia.com · 202-887-0568

  • The Center for Vulvovaginal Disorders, Tampa, Florida, United States

    Contact: Study coordinator (Jill Krapf, MD) · jillkrapf@gmail.com · 813-358-7634

  • The Center for Vulvovaginal Disorders - New York, New York, New York, United States

    Contact: Study coordinator (Andrew T Goldstein, MD) · obstetrics@yahoo.com · 410-279-0209
Study leads

  • Andrew T Goldstein, MD

    Principal Investigator

    Center for Vulvovaginal Disorders

View source on ClinicalTrials.gov(opens in a new tab)